Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (40118)	5/19/2003 12:08:00 PM
From: Jorj X Mckie	Read Replies (1) \| Respond to of 57110

qlti definitely looks broken.

To: tuck who wrote (40118)	5/19/2003 2:37:49 PM
From: stevenallen	Respond to of 57110

great call on QLTI - I ss @ 11.04 right after your post and just checked in to find I got filled on a cover @ 10.4 - love that quick coin - THANKS!!!

To: tuck who wrote (40118)	5/19/2003 6:18:50 PM
From: Libbyt	Read Replies (2) \| Respond to of 57110

REGN... Do you have any thoughts on REGN? It was mentioned today as a company that might benefit from the news DNA released today....in that they have a similar drug currently in development? Regeneron shares ride Genentech stock surge Monday May 19, 4:26 pm ET (Updates with closing stock prices) NEW YORK, May 19 (Reuters) - Regeneron Pharmaceuticals Inc. (NasdaqNM:REGN - News) shares climbed more than 40 percent on Monday as they road the coattails of Genentech Inc. (NYSE:DNA - News), which reported positive news for an experimental cancer drug similar to one Regeneron is developing, an analyst said. Genentech on Monday said data from a late-stage trial of its experimental colon cancer drug, Avastin, showed it extends life far longer than had been expected. Genentech's stock climbed nearly 45 percent on the news. Avastin slows tumor growth by cutting off its supply of blood and oxygen. Regeneron's cancer drug, known as VEGF Trap, while in a much earlier stage of clinical trials, uses a similar mechanism to fight tumors. Regeneron, also announced some moderately positive news for its experimental obesity drug at a weekend meeting. The Tarrytown, New York-based company said a late-stage trial of its obesity drug, Axokine, identified patients most likely to benefit from the drug. But average weight loss of patients was modest and limited by patients who developed a resistance to it, Regeneron said. SG Cowen Securities analyst Yaron Werber said both the Genentech and Axokine news were likely factors in Monday's Regeneron stock surge. "It's probably related more to VEGF Trap," Werber said, calling it a promising drug. He said he believed the Regeneron drug is more potent than Genentech's. Shares of Regeneron closed up $2.93, or 41.5 percent, at $9.99 on Nasdaq, where it was among the day's top percentage gainers. ********** Thanks!